PMID: 3753393May 1, 1986Paper

The influence of fish oil diet and norepinephrine treatment on fatty acid composition of rat heart phospholipids and the positional fatty acid distribution in phosphatidylethanolamine

Basic Research in Cardiology
A MontfoortJ M Lamers

Abstract

The effect of chronic norepinephrine (NE) administration with increasing dosage from 1-4 mg/kg over a period of 2 weeks was studied on cardiac phospholipids and their fatty acid distribution in rats. Animals were fed a control diet or a 10% cod liver oil (CLO)-enriched diet. The relative distribution of various polyunsaturated fatty acids esterified to the 1- and 2-position of the phosphatidylethanolamine fraction was estimated. NE stress during control feeding significantly reduced the total phospholipid content in rat heart. No differences in the phospholipid class distribution were found. However, CLO feeding as well as chronic NE administration resulted in a decrease of omega 6 fatty acids, mainly C 18:2 omega 6 and C 20:4 omega 6, which was compensated with an increase in omega 3 fatty acids, mainly C 20:5 omega 3 and C 22:6 omega 3. The changes in fatty acid composition qualitatively agree with those reported by Gudbjarnason et al. (23), except that the mortality in our NE-treated control or CLO-fed groups was considerably lower. It can probably be attributed to a different mode of NE administration. On the other hand, at the end of the CLO feeding period in rats treated with NE or not, comparing with control fed rats wit...Continue Reading

References

Aug 1, 1978·The American Journal of Clinical Nutrition·T O von LossonczyR J Hermus
Dec 1, 1977·FEBS Letters·G E DobretsovY A Vladimirov
Sep 1, 1978·The Journal of Clinical Investigation·B E SobelM S Klein
Jan 1, 1978·Advances in Cardiology·S GudbjarnasonJ Hallgrímsson
Jul 22, 1976·The New England Journal of Medicine·G L Nicolson, G Poste
Aug 1, 1977·Journal of Molecular and Cellular Cardiology·S C Vasdev, K J Kako
Dec 1, 1977·The Journal of Clinical Investigation·K P BurtonL M Buja
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Dec 7, 1966·Biochimica Et Biophysica Acta·L M van Golde, L L van Deenen
Apr 29, 1969·Biochimica Et Biophysica Acta·L M van GoldeL L van Deenen
Feb 1, 1966·The American Journal of Physiology·R A Kreisberg
Oct 15, 1984·Biochemical and Biophysical Research Communications·W B WeglickiI T Mak
Nov 1, 1983·Toxicology and Applied Pharmacology·S Mallov
Feb 1, 1984·Scandinavian Journal of Clinical and Laboratory Investigation·C Popp-SnijdersE A van der Veen
Mar 1, 1981·Progress in Cardiovascular Diseases·A J Liedtke
Mar 1, 1982·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S H GoodnightD R Illingworth
Apr 23, 1981·Biochimica Et Biophysica Acta·A Emilsson, S Gudbjarnason
Jan 1, 1981·Circulation Research·A M Katz, F C Messineo

❮ Previous
Next ❯

Citations

Jan 19, 2007·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Aurélie Gousset-DupontSylviane Tardivel
Nov 27, 2007·International Journal of Cardiology·Arie O VerkerkRuben Coronel
Jan 9, 2015·Journal of Human Genetics·Gerhard P ShipleyAlan J Redd
Jun 12, 2012·Nature Reviews. Microbiology·Jonathan LombardDavid Moreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.